The blood samples were tested using an anti-SARS-CoV-2 S enzyme immunoassay (Elecsys anti-SARS-CoV-2 S RUO; Roche Diagnostics, Mannheim, Germany), which detects antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein, according to the manufacturer’s instructions. Values below 0.8 U/mL were considered negative.
Elecsys anti sars cov 2 s ruo
Manufactured by Roche
Sourced in Switzerland
The Elecsys Anti-SARS-CoV-2 S RUO is a laboratory-based assay used for the quantitative determination of antibodies to the SARS-CoV-2 spike protein. It is intended for research use only and not for use in diagnostic procedures.
Automatically generated - may contain errors
Lab products found in correlation
10 protocols using elecsys anti sars cov 2 s ruo
1
SARS-CoV-2 Spike Protein Antibody Assay
2
Quantifying Anti-SARS-CoV-2 Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We assessed anti–SARS-CoV-2 antibodies for all participants of the third survey and retrieved those data for the case-control subsets. We quantitatively measured antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein by using the AdviseDx SARS-CoV-2 IgG II assay (Abbott) (immunoglobulin [Ig] G [IgG]) and Elecsys Anti-SARS-CoV-2 S RUO (Roche) (predominantly IgG, also IgA and IgM). The sensitivity and specificity were reported as 97.6% and 100%, respectively, for the Abbott assay [15 (link)], and 97.9% and 99.9%, respectively, for the Roche assay [16 (link)]. We also qualitatively measured antibodies against SARS-CoV-2 nucleocapsid protein using the SARS-CoV-2 IgG assay (Abbott) and Elecsys Anti-SARS-CoV-2 RUO (Roche), and used these data to exclude those with possible infection in the past. The sensitivity and specificity were 100% and 99.9%, respectively, for the Abbott assay [17 (link)], and 99.5% and 99.8%, respectively, for the Roche assay [18 (link)].
3
SARS-CoV-2 Spike Protein Antibody Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Titers of serum total antibody (immunoglobulins M and G) to the SARS-CoV-2 spike protein receptor-binding domain were tested by enzyme-linked immunosorbent assay (Elecsys Anti–SARS-CoV-2 S RUO; Roche, Basel, Switzerland) according to the manufacturer’s instructions.
4
Quantification of SARS-CoV-2 Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The serum total antibody (IgM and IgG) titre to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein receptor-binding domain was assessed by an enzyme-linked immunosorbent assay (ELISA) using Elecsys Anti-SARS-CoV-2 S RUO (Roche, Basel, Switzerland) according to the manufacturer's instructions.
5
Quantifying SARS-CoV-2 Antibody Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We assessed anti–SARS-CoV-2 antibodies for all participants at baseline and follow-up and retrieved those data for the case-control subsets. We quantitatively measured antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein by using the AdviseDx SARS-CoV-2 IgG II assay (Abbott) (immunoglobulin [Ig] G [IgG]) and Elecsys® Anti-SARS-CoV-2 S RUO (Roche) (including IgG). We also qualitatively measured antibodies against SARS-CoV-2 nucleocapsid protein using the SARS-CoV-2 IgG assay (Abbott) and Elecsys® Anti-SARS-CoV-2 RUO (Roche), and used these data to exclude those with the possible infection before the baseline survey and to identify those who experienced breakthrough infection during the follow-up period. The sensitivity and specificity were 100% and 99.9%, respectively, for the Abbott assay [13 ], and 99.5% and 99.8%, respectively, for the Roche assay [14 ].
6
SARS-CoV-2 Antibody Titer Measurement
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Antibody titters to S protein of SARS-CoV-2 in the patient’s plasma were measured by SRL, Inc. using Elecsys anti-SARS-CoV-2 S RUO (Roche Diagnostics K.K.). Values >0.8 U/mL were determined to be positive.
7
Quantifying Anti-SARS-CoV-2 IgG Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We underwent 1 to 5 blood tests per one patient after each vaccination time point. We measured the IgG antibodies against the SARS-CoV-2 S protein receptor-binding domain. The blood samples collected for regular evaluation were stored and used for analysis. The anti-SARS-CoV-2 S IgG antibody titer was quantitatively detected with a double-antigen sandwich-based electrochemiluminescence immunoassay (ECLIA), using the Elecsys® Anti-SARS-CoV-2 S RUO (Roche Diagnostics, Mélan, France). According to the manufacturer’s data, the values above 0.80 U/mL are considered to indicate seropositivity and the values above 15 U/mL had a likelihood of 100% to confer in vitro neutralization to SARS-CoV-2. We defined seropositivity as an antibody of ≥ 0.8 U/mL.
8
Longitudinal SARS-CoV-2 Antibody Dynamics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
SARS-CoV-2 anti-spike antibody measurements were performed on serum obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO (Roche Diagnostics, Rotkreuz, Switzerland) on a Cobas 6000 (Roche Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay method [18 (link)]. Samples were collected before the first dose of the BNT162b2 vaccine was administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the second vaccination. The measurement range of the antibody assay was 0.4–250, and samples with an antibody titer of ≥250 U/mL were assayed again after dilution.
9
COVID-19 Antibody Response Quantification
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum samples were tested for SARS-CoV-2 antibodies (immunoglobulin G [IgG] levels) using the Elecsys® Anti-SARS-CoV-2 S RUO (Roche Diagnostics, Basel, Switzerland) test system. Antibody titers > 0.8 U/mL were considered as positive immune response to vaccination.
10
SARS-CoV-2 Antibody Measurement Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
IgG antibodies specific to the S1 subunit of the spike protein (anti-spike IgG) were measured using Roche kits (Elecsys® Anti-SARS-CoV-2 S RUO; Roche Diagnostics K.K., Tokyo, Japan). Positive signals were reported at a cut off index ≥ 0.8 U/mL. IgG antibodies specific to the SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid IgG) were measured using Roche kits (Elecsys® Anti-SARS-CoV-2, Roche Diagnostics K.K.). Positive signals were reported at a cut off index ≥ 1.0 U/mL. These immunoassays were performed according to the manufacturer's instructions on a Cobas 8000 e801 module (Roche Diagnostics K.K.). We defined positive or false positive as described following. Both anti-nucleocapsid IgG and anti-spike IgG positive findings indicate infected participants, whereas negative of either is false positive.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!